コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 naling pathways after exposure to 4.86 mug/L fluticasone propionate.
2 combination with an inhaled glucocorticoid, fluticasone propionate.
3 daily for 7 days inhaled (via spacer device) fluticasone propionate.
4 group than in controls 4-12 h after inhaled fluticasone propionate.
5 C57BL/6 mice were intranasally dosed with fluticasone propionate (1 mg/kg) or vehicle (dimethyl su
6 ma and treated them for 30 days with inhaled fluticasone propionate (1,760 microg/day) followed by a
7 (with the exception of PEF rates for inhaled fluticasone propionate 100 micrograms) or placebo treatm
8 allergy were treated with run-in medication (fluticasone propionate 100 mug bid) during 2 weeks befor
9 d, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young chil
10 re not under control by 3 months, open-label fluticasone propionate 100 mug twice daily was added to
11 bo (n = 96) for 48 weeks and maintained with fluticasone propionate, 176 mug/d (6-11 years old), or 2
12 ng patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy
13 wder 100 or 500 micrograms twice daily, oral fluticasone propionate 20 mg once daily, or placebo duri
14 lind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 microg (n = 67) twice dail
15 Each child was randomized to 1 of 3 cohorts: fluticasone propionate, 50 mug, with placebo; fluticason
16 luticasone propionate, 50 mug, with placebo; fluticasone propionate, 50 mug, with salmeterol, 25 mug;
17 althy adult volunteers randomized 2:1 to (i) fluticasone propionate 500 mcg bd daily or (ii) no treat
18 twice daily), and the inhaled glucocorticoid fluticasone propionate (500 mug twice daily) during a 6-
19 A (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-up to double to quintupl
20 percentage difference, -15%; P = .0115), and fluticasone propionate (absolute difference, -1.64; perc
21 The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantl
22 inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years.
23 ve with a combination product (100 microg of fluticasone propionate and 50 microg of salmeterol [FSC]
24 gate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol a
25 n the 12 h after dosing, we monitored plasma fluticasone propionate and cortisol concentrations by ma
28 activation of the glucocorticoid receptor by fluticasone propionate and inhibition of fin regeneratio
29 owders containing the inhaled corticosteroid fluticasone propionate and long-acting beta2-agonist sal
30 (inflammation and bronchoconstriction) with fluticasone propionate and salmeterol in a combination p
31 COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone fur
32 over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of
33 oth TH1 and TH2 cytokines, was additive with fluticasone propionate, and inhibited cytokine release f
34 est that the therapeutic benefits of inhaled fluticasone propionate are mediated through topical effe
35 whether the therapeutic benefits of inhaled fluticasone propionate are mediated through topical or s
38 confirming the presence of peaks related to fluticasone propionate at 1743, 1661, and 1700 cm(-1), s
39 aring salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice dai
40 ve asthma predictive index to treatment with fluticasone propionate (at a dose of 88 mug twice daily)
41 tiotropium, 100 mug salmeterol, and 1000 mug fluticasone propionate daily for 6 weeks and were then r
43 r the structural study of the steroidal drug fluticasone propionate extracted from a commercial formu
44 fits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting
45 uiring daily therapy with 500 mug or more of fluticasone propionate (FLU) with or without a long-acti
49 lind, crossover study evaluating twice daily fluticasone propionate (FP) 100 mug, FP 500 mug and plac
50 crossover study and inhaled single doses of fluticasone propionate (FP) 100 mug, FP 500 mug, salmete
51 ment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 mi
52 , mean age 64 yr, were randomized to receive fluticasone propionate (FP) 500 microg twice daily (376
53 e efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patien
55 p a FDC of DPIs for market-leading medicines-fluticasone propionate (FP) and salmeterol xinafoate (SA
56 ce were studied to determine whether inhaled fluticasone propionate (FP) could attenuate airway infla
57 we determined the effects of salmeterol and fluticasone propionate (FP) in seven steroid-naive patie
58 aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinoph
59 ); low (L), medium (M) and high (H) doses of fluticasone propionate (FP) L: 330 microg, M: 770 microg
60 ddition, the effects of IL-4, IFN-gamma, and fluticasone propionate (FP) on nasal epithelial cells we
61 antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Qaw in 12 patients with m
62 the efficacy of MP-AzeFlu (Dymista((R)) ) vs fluticasone propionate (FP), (both 1 spray/nostril bid),
63 hages, matured in the presence or absence of fluticasone propionate (FP), and their ability to initia
64 ect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition o
65 ent study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasocons
66 H3N2 and either or not treated with inhaled fluticasone propionate (FP), systemic corticosteroids (P
67 estigated the effects of importin-7 siRNA on fluticasone propionate (FP)-induced GR nuclear localizat
68 age I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 w
69 and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 microg daily) on these p
70 29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-t
75 the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in c
77 and primary cultures], roflumilast enhanced fluticasone propionate-induced GRE-dependent transcripti
78 ge studies in mice demonstrate that the ICS, fluticasone propionate, inhibited type 2-driven eosinoph
81 Two puffs (total dose, 200 microgram) of fluticasone propionate (n = 47) or placebo nasal spray (
82 BI 671800 (50, 200, and 400 mg twice daily), fluticasone propionate nasal spray (200 mug once daily),
83 the results after adjustment for open-label fluticasone propionate, nor between the two groups in th
84 this study was to assess effects of inhaled fluticasone propionate on rhinovirus infection in vivo,
85 0 to 500 mug, and >500 mug, respectively, of fluticasone propionate or equivalent for adults with ast
86 ly dose," which is defined as 200-250 mug of fluticasone propionate or equivalent, representing the d
87 core >/=1.5) after uptitration to 1000 mug/d fluticasone propionate or greater were randomized to 3 o
90 ly (fluticasone propionate), INCS on demand (fluticasone propionate) or oral antihistamine on demand
91 wer in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95
92 ukast (our primary hypothesis) or once-daily fluticasone propionate plus salmeterol (our secondary hy
93 xacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone al
94 nd, run-in period were randomized to inhaled fluticasone propionate powder 100 or 500 micrograms twic
95 nolone acetonide, clobetasol propionate, and fluticasone propionate) predominantly accounted for GR a
96 treatment with the synthetic glucocorticoid fluticasone propionate prevented chitosan-induced barrie
99 ve analyses (AUC12) was higher with the oral fluticasone propionate than with the two inhaled flutica
100 was performed in fluticasone furoate (FF) or fluticasone propionate-treated patients with asthma from
103 point were significantly higher with inhaled fluticasone propionate treatment regimens than with oral
104 tes, both 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily significantly increas
105 evaluates 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily, each compared with p
107 rdation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppre
108 astine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the hig
110 propionate treatment regimens than with oral fluticasone propionate (with the exception of PEF rates